冻干制剂 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Receptor activation raises intracellular cyclic AMP through Gs coupling, which promotes glucose-dependent insulin release and suppresses glucagon secretion when blood glucose is elevated. Effects outside the pancreas include slower gastric emptying and altered appetite signalling in the hypothalamus and hindbrain. The relative contribution of each tissue to overall metabolic outcomes remains an area of active investigation. Central mechanisms in particular are inferred mainly from animal models and indirect human measures rather than direct observation.
Serum protein binding dominates the pharmacokinetic profile. The attached chain associates strongly with albumin, shielding the peptide from enzymatic attack and slowing filtration by the kidney. This interaction extends the circulation half-life to roughly one week in humans, which supports weekly administration intervals. An oral version pairs the peptide with an absorption enhancer that transiently alters gastric epithelium, permitting limited uptake; bioavailability by that route is substantially lower than by injection.
Semaglutide belongs to the glucagon-like peptide-1 receptor agonist class, a group of synthetic peptides that imitate an incretin hormone released by intestinal L cells after food intake. Native GLP-1 circulates for only a few minutes because dipeptidyl peptidase-4 cleaves it rapidly. The hormone acts on pancreatic islets, the gastrointestinal tract, and several brain regions. Because the natural peptide is short-lived, development work concentrated on analogues that keep receptor activity while resisting enzymatic breakdown and renal clearance.
GLP-1 receptors are expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises cyclic AMP, enhances glucose-dependent insulin secretion, and suppresses glucagon release when blood glucose is high. Effects on gastric emptying and on hypothalamic appetite circuits reduce energy intake. Because insulin release remains glucose-dependent, the risk of hypoglycemia is low when the drug is used alone. The precise contribution of each pathway to body weight change in humans remains an area of active investigation.
Clinical studies of semaglutide generally measure glycated hemoglobin, fasting plasma glucose, body weight, and composite cardiovascular endpoints. The SUSTAIN program enrolled adults with type 2 diabetes, while the STEP program focused on obesity without diabetes. Administration follows a stepwise escalation schedule designed to limit gastrointestinal effects during the first weeks. Reported outcomes include mean percentage weight change, the proportion of participants reaching defined weight-loss thresholds, and rates of nausea, vomiting, and diarrhea. Long-term data on durability after treatment stops are still limited and remain a topic of ongoing research.
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, developed by Novo Nordisk and first approved in 2017 for type 2 diabetes. It belongs to the incretin mimetic class, a group of agents that reproduce the glucose-dependent actions of endogenous GLP-1. The molecule was engineered to resist degradation by dipeptidyl peptidase-4 and to bind serum albumin, extending its half-life from minutes to roughly one week. Approval for chronic weight management followed in 2021, based on large cardiovascular and obesity outcome trials.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide, GLP-1 receptor agonist | 31 amino acid residues |
| Molecular formula | C187H291N45O59 | free peptide, no counter-ion |
| Approximate mass | 4114 Da | matches theoretical value |
| Receptor target | Glucagon-like peptide-1 receptor | Gs-coupled, cyclic AMP pathway |
| Circulation half-life | About one week in humans | extended by albumin association |
Lyophilised material appears as a white to off-white cake or powder that is hygroscopic, and containers are usually equilibrated to room temperature before opening to limit condensation. Dissolution is performed in water, phosphate-buffered saline, or a mildly alkaline buffer, since solubility rises above neutral pH. Gentle inversion or low-speed mixing is preferred, because vigorous vortexing can promote surface denaturation and aggregation. Complete dissolution may require several minutes, and brief sonication is sometimes applied. Passing the solution through a 0.22 micrometre membrane removes particulates but does not by itself sterilise the liquid.
Storage at minus 20 degrees Celsius or lower in a desiccated container preserves the peptide for extended periods, while working solutions are commonly held at two to eight degrees Celsius for short intervals. Light exposure and repeated freeze-thaw cycles accelerate degradation, so dividing material into single-use aliquots is generally recommended. Adsorption to glass and plastic surfaces can lower the measured concentration of dilute solutions, particularly below one milligram per millilitre. The degradation routes most often reported for GLP-1 analogues are deamidation, methionine oxidation, and backbone hydrolysis. Relative rates under specific conditions are frequently described only for individual formulations.
Stability studies focus on deamidation of asparagine and glutamine residues, oxidation of methionine, and aggregation into higher-order species. The fatty acid side chain adds susceptibility to oxidative change and can promote self-association at high concentration. Lyophilised material is comparatively robust when kept cold and dry, while aqueous solutions require refrigeration and protection from light. Forced degradation experiments under heat, acid, base, and peroxide conditions establish the specificity of each analytical method. Which degradation route dominates under real storage conditions depends on the formulation and stays formulation-specific.
Handling guidance for research quantities calls for single-use aliquots, an inert atmosphere where practical, and avoidance of repeated freeze-thaw cycles that accelerate aggregation. Certificates of analysis typically report purity by peak area, water content, counter-ion identity, and residual solvent levels. In the scientific literature the compound is usually described by its full amino acid sequence, its registry number, or its structural class rather than by any proprietary label. Reporting standards vary between journals, and reviewers increasingly request raw chromatograms alongside tabulated purity figures. Whether current purity thresholds are adequate for every experimental context is debated.
Reversed-phase high-performance liquid chromatography with ultraviolet detection is the dominant approach for peptide purity assessment, usually paired with mass spectrometry to confirm molecular mass and sequence. Peptide mapping by enzymatic digestion and tandem mass spectrometry locates modifications such as deamidation and oxidation. Quantitation in plasma matrices can be performed by LC-MS/MS after solid-phase extraction. Method validation follows general guidance on accuracy, precision, linearity, and limits of detection. Comparability of results between laboratories, when no shared reference standard is available, remains an open question.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1 (GLP-1), a hormone released from intestinal L-cells after food intake. The compound belongs to the incretin mimetic class and acts at GLP-1 receptors distributed across pancreatic, gastrointestinal, cardiovascular, and central nervous system tissues. Compared with native GLP-1, the molecule carries structural changes that extend its activity from minutes to roughly one week. It is studied for glycemic control in type 2 diabetes and for weight management, and its effects on cardiovascular and other outcomes remain active research areas.
Receptor binding triggers G protein signaling that raises intracellular cyclic AMP in pancreatic beta cells. Insulin release follows in a glucose-dependent manner, so secretion increases when blood glucose is elevated and diminishes when it is not. The same signaling suppresses glucagon release from alpha cells and slows gastric emptying, which blunts the post-meal glucose rise. In the brain, receptor activation in regions such as the arcuate nucleus is associated with reduced appetite and lower energy intake. How much each of these effects contributes to overall weight change is not fully settled.
Two structural features account for the prolonged half-life of semaglutide. A modified amino acid at position 8 resists cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GLP-1. A fatty diacid side chain binds serum albumin, which limits renal clearance and protects the peptide from enzymatic breakdown. These modifications yield a plasma half-life of approximately one week in humans, allowing once-weekly administration. The relationship between plasma concentration and clinical effect varies between individuals, and sources of that variability are still being characterized.
容器与密封系统同样参与稳定性表现。硅油涂层、胶塞材质与顶空氧含量可能改变聚集速率与氧化水平。分析结果因此需要在完整包装形式下评估，而不能仅凭原料药数据推断。法规文件通常要求同时提交批次数据与代表性容器中的稳定性趋势。
关于降解产物的免疫原性风险，文献中仍有讨论空间。体外聚集水平与临床免疫反应之间的定量关系尚未确立。多数公开研究只报告理化指标，缺少长期随访的对应数据。这一问题在生物类似物比对中尤其受到关注。
市售注射用制剂通常要求在二至八摄氏度冷藏保存，并避免光照与冻结。部分多剂量笔在首次使用后允许在不超过三十摄氏度的环境中存放有限周数，具体期限由辅料与防腐剂体系决定。反复冻融会促进肽链聚集并改变可见颗粒计数，因此应予避免。冻干粉末在干燥、避光、低温条件下更为稳定。溶液配制后宜使用低吸附容器，以减少肽类在塑料或玻璃表面的损失。
Okazaki fragments Short sequences of nucleotides which are synthesized discontinuously by DNA polymerase and later linked together by DNA ligase to create the lagging strand during DNA replication. Okazaki fragments are the consequence of the unidirectionality of DNA polymerase, which only works in the 5' to 3' direction.
A second controversial aspect of the award was that eight months before Banting's and Best's paper, the Romanian physiologist Nicolae Paulescu had reported the discovery of a pancreas extract that he dubbed pancrein, which lowered blood glucose concentration. Banting and Best even cited him in their paper, but misinterpreted his findings, purportedly because of an error in translation from French. Best publicly apologized for that mistake many years later.
The first aircraft carrying troopers from the 2–325th touched down at Point Salines 17 hours after H-Hour notification. In March 1988, a brigade task force made up of two battalions from the 504th Infantry and 3d Battalion (Airborne), 505th Infantry, conducted a parachute insertion and air/land operation into Honduras as part of Operation Golden Pheasant. The deployment was billed as a joint training exercise, but the paratroopers were ready to fight. The deployment caused the Sandinistas to withdraw to Nicaragua. Operation Golden Pheasant prepared the paratroopers for future combat in an increasingly unstable world.
==== 4.D Polysaccharide Synthase/Exporters ==== 4.D.1 The Putative Vectorial Glycosyl Polymerization (VGP) Family 4.D.2 The Glycosyl Transferase 2 (GT2) Family 4.D.3 The Glycan Glucosyl Transferase (OpgH) Family
Sources: en.wikipedia.org
==== MeSH D12.776.964.775.350 – gene products, gag (gene) ==== MeSH D12.776.964.775.350.320 – fusion proteins, gag-onc MeSH D12.776.964.775.350.320.700 – oncogene protein p65(gag-jun) MeSH D12.776.964.775.350.325 – fusion proteins, gag-pol MeSH D12.776.964.775.350.400 – hiv core protein p24
=== Fentanyl analogs === Fentanyl analogs are types of fentanyl with various chemical modifications on any number of positions of the molecule, but still maintain, or even exceed, its pharmacological effects. Many fentanyl analogs are termed "designer drugs" because they are synthesized solely to be used illicitly. Carfentanil, a fentanyl analog, has an additional methyl ester group attached to the 4 position. Carfentanil is 20–30 times as potent as fentanyl and is common in the illicit drug chain. The drug is commonly used to tranquilize elephants and other large animals.
Metabolically label O-GlcNAc to install O-GlcNAz onto proteins Use click chemistry to link IsoTaG probe to O-GlcNAz Use streptavidin beads to enrich for tagged proteins Treat beads with trypsin to release non-modified peptides Cleave isotopically recoded glycopeptides from beads using mild acid Obtain a full-scan mass spectrum from isotopically recoded glycopeptides Apply algorithm to detect unique isotope signature from probe Perform tandem MS on the isotopically recoded species to obtain glycopeptide amino acid sequences Search protein database for identified sequences Other methodologies have been developed for quantitative profiling of O-GlcNAc using differential isotopic labeling. Example probes generally consist of a biotin affinity tag, a cleavable linker (acid- or photo-cleavable), a heavy or light isotopic tag, and an alkyne. O-GlcNAc modification has also been recently reported on tyrosine residues, though these represent roughly 5% of all O-GlcNAc modifications.
Sources: en.wikipedia.org
Derek Malcolm of the Evening Standard felt that the movie was a "dim reworking of Fatal Attraction" and noted: "Larter as the pathological minx is the best thing about it." Obsessed opened No. 1 in its opening weekend with $28 million, and making a total domestic gross of $68 million, becoming Larter's second highest-grossing film in North-America. Larter was nominated for a third time for a Teen Choice Award when she and Beyoncé were nominated for the Teen Choice Award for Choice Movie: Rumble at the 2009 Teen Choice Awards and an MTV Movie Award for Best Fight both for Obsessed. Larter reprised her role of Claire Redfield in Resident Evil: Afterlife (2010), which was filmed in 3D and saw her character ambushed and mentally manipulated by the fictional Umbrella Corporation, before she is rescued by Alice (Milla Jovovich). Like the previous Resident Evil entries, the film received negative reviews but became a major commercial success, earning $296 million worldwide. On returning to the role of Claire, Larter told JoBlo.com: "I guess people liked me as her... I'm excited that they brought me back... to work with the man [Paul W. S. Anderson] who really created this world and this vision was what excited me about joining this next installment". In 2010, Larter appeared as the title character in a short film for Absolut Vodka entitled "Lemon Drop". After the release of Afterlife, Larter went on hiatus to focus on her family.
=== EC 7.3 Catalysing the translocation of inorganic anions === This subclass contains translocases that transfer inorganic cations anions. Subclasses are based on the reaction processes that provide the driving force for the translocation. At present only one subclass is represented: EC 7.3.2 Translocation of inorganic anions linked to the hydrolysis of a nucleoside triphosphate.
=== Role in aging === The relationship between RAGE signaling and aging has been a growing focus of research, particularly in the context of cellular senescence and inflammaging—chronic, low-grade inflammation associated with aging. RAGE has been implicated in promoting cellular senescence, a permanent state of cell-cycle arrest, which contributes to the accumulation of dysfunctional cells that secrete pro-inflammatory factors, collectively referred to as the senescence-associated secretory phenotype (SASP). A study conducted in 2022 demonstrated that the activation of RAGE by AGEs in aged tissues leads to the accumulation of senescent cells, thereby exacerbating tissue inflammation and contributing to age-related diseases. This study also noted that the upregulation of RAGE in aged cells increased the secretion of SASP factors, such as interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α), both of which are key mediators of inflammaging. Another recent investigation from 2023 found that mice deficient in RAGE exhibited reduced markers of senescence and systemic inflammation compared to age-matched controls, suggesting that targeting RAGE signaling may be a promising approach to mitigate the adverse effects of aging and extend healthspan. These findings highlight the role of RAGE as a crucial regulator of the inflammatory milieu associated with aging, providing potential avenues for therapeutic interventions aimed at reducing age-related inflammatory diseases.
=== Other countries === Austria: Word of the year (Austria), since 1999. The event is organised by the Society for Austrian German (GSÖD). Notable selections include the 52-letter word Bundespräsidentenstichwahlwiederholungsverschiebung (2016), and more recently, 'Elk Emil', in 2025. In Germany, a Wort des Jahres has been selected since 1972 (for the year 1971) by the Society of the German Language. In addition, an Unwort des Jahres (Un-word of the year or Most Unpleasant Word of the Year) has been nominated since 1991, for a word or phrase in public speech deemed insulting or socially inappropriate (such as "Überfremdung"). Similar selections are made each year since 1999 in Austria, 2002 in Liechtenstein, and 2003 in Switzerland. Since 2008, language publisher Langenscheidt supports a search for the German youth word of the year, which aims to find new words entering the language through the vernacular of young people. In addition, several German dialects have their own Wort des Jahres selection: de:Plattdeutsches Wort des Jahres, de:Wort des Jahres (Sachsen), and de:Wort des Jahres (Südtirol). In Denmark, the Word of the year has been selected by Mål og Mæle, a popular science language magazine, during 2006–2012 and since 2009 also by the Sproglaboratoriet radio program of the DR P1 radio channel in collaboration with Dansk Sprognævn (Danish Language Council). Japan has held an annual word of the year contest called the "New Word/Trendy Phrase Award" (Shingo ryūkōgo taishō) since 1984, sponsored by the Jiyu Kokuminsha publisher (by U-CAN since 2004).
Sources: en.wikipedia.org
It is a synthetic peptide of 31 amino acids, built to resemble the natural incretin hormone GLP-1. Because of its size and composition it is handled analytically like other therapeutic peptides, using chromatographic and mass spectrometric methods rather than the techniques typical of small organic drugs.
The substitution at position 8 removes the site recognised by dipeptidyl peptidase-4, the enzyme that destroys the native hormone within minutes. The linked lipophilic chain then binds circulating albumin, which further limits access by degradative enzymes and reduces renal loss. Together these features lengthen the effective circulation time considerably.
It acts at the glucagon-like peptide-1 receptor, a G protein-coupled receptor that signals mainly through cyclic AMP. Activation is glucose dependent, meaning insulin release is stimulated more strongly when blood glucose is already elevated. Other tissues carrying the same receptor respond as well, which explains effects beyond glucose control.
It is given either as a once-weekly subcutaneous injection or as an oral tablet taken once daily. The two forms use different absorption strategies, so they are not interchangeable on a milligram-for-milligram basis.